Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fabrazyme on Progression of Renal Disease and Significant Clinical Events in Patients With Fabry Disease
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 23 Mar 2021 New trial record
- 12 Mar 2021 Results presented in a Sanofi media release.